Da Zen Theranostics, Inc. (Da Zen) has developed revolutionary therapies for cancer detection, imaging, and treatment in order to prolong survival and improve quality of life for patients with cancer. The innovative research at Da Zen has led to the discovery and advancement of proprietary products and technologies that enable more effective identification and targeting of cancer cells with a higher degree of specificity. Not only do Da Zen’s anti-cancer therapies successfully bypass problems typically associated with cancer treatment, such as toxicity and resistance, but they also confine therapy to tumor cells for an extended period of time. In addition, Da Zen’s patented targeting agent has a light-emitting property which has the potential to assist in the visualization of tumor cells during surgery.
Taking a unique approach to develop and test therapies in clinical trials settings has enabled Da Zen to more effectively identify, target, and treat cancer, regardless of tumor location and type. Da Zen’s advanced patented therapies support the implementation of more cost-effective strategies in the development of novel cancer therapies – essentially providing a competitive and sustainable advantage to developing better anti-cancer drugs and technology more quickly and safely.
The innovation at Da Zen is a result of the close collaboration of three Institutions highly regarded in cancer research: Cedars-Sinai Medical Center (Los Angeles, CA), Emory University (Atlanta, GA), and Georgia State University (Atlanta, GA). Da Zen is supported by the rigor of grant-funded research, a diverse and experienced scientific team, as well as independent laboratories, for confirmation of research and technology in animal studies. Dr. Leland W.K. Chung, a world-renowned prostate cancer researcher, is founder and Chairman of the Board of Da Zen.
To date, Da Zen has seventeen patent applications of which five are granted patents. Of these, seven are exclusively licensed, another seven are proprietary to the company, two granted in China, and one granted in Europe for a total of seventeen. Dr. Chung is the inventor of all seven exclusively licensed patents and many proprietary patent applications. Da Zen’s technology and associated patents are now available for commercial release. The expanse of 12+ years of research at Da Zen has been funded by institutions with non-dilutive capital.
With over a decade of research devoted to innovative therapies, Da Zen is currently conducting pre-clinical Investigational New Drug (IND) studies in a Good Laboratory Practice (GLP) facility. Da Zen has been granted FDA approval to begin human clinical trials in hospitals and clinics to assess the efficacy of its targeted therapies. There are two trial sites: Cidars Sinar Medical Centers and HOAG Cancer Centers. It is about to complete the Phase I trials and start Phase II. Notably, these trials will be aided by new companion diagnostic biomarkers for patient selection and monitoring of therapeutic response.
Da Zen believes this novel approach is a paradigm shift for cancer detection and treatment that will provide therapeutic options where no effective ones currently exist.
Taking a unique approach to develop and test therapies in clinical trials settings has enabled Da Zen to more effectively identify, target, and treat cancer, regardless of tumor location and type. Da Zen’s advanced patented therapies support the implementation of more cost-effective strategies in the development of novel cancer therapies – essentially providing a competitive and sustainable advantage to developing better anti-cancer drugs and technology more quickly and safely.
The innovation at Da Zen is a result of the close collaboration of three Institutions highly regarded in cancer research: Cedars-Sinai Medical Center (Los Angeles, CA), Emory University (Atlanta, GA), and Georgia State University (Atlanta, GA). Da Zen is supported by the rigor of grant-funded research, a diverse and experienced scientific team, as well as independent laboratories, for confirmation of research and technology in animal studies. Dr. Leland W.K. Chung, a world-renowned prostate cancer researcher, is founder and Chairman of the Board of Da Zen.
To date, Da Zen has seventeen patent applications of which five are granted patents. Of these, seven are exclusively licensed, another seven are proprietary to the company, two granted in China, and one granted in Europe for a total of seventeen. Dr. Chung is the inventor of all seven exclusively licensed patents and many proprietary patent applications. Da Zen’s technology and associated patents are now available for commercial release. The expanse of 12+ years of research at Da Zen has been funded by institutions with non-dilutive capital.
With over a decade of research devoted to innovative therapies, Da Zen is currently conducting pre-clinical Investigational New Drug (IND) studies in a Good Laboratory Practice (GLP) facility. Da Zen has been granted FDA approval to begin human clinical trials in hospitals and clinics to assess the efficacy of its targeted therapies. There are two trial sites: Cidars Sinar Medical Centers and HOAG Cancer Centers. It is about to complete the Phase I trials and start Phase II. Notably, these trials will be aided by new companion diagnostic biomarkers for patient selection and monitoring of therapeutic response.
Da Zen believes this novel approach is a paradigm shift for cancer detection and treatment that will provide therapeutic options where no effective ones currently exist.
